Yuhan Corporation announced that it will receive a milestone payment of USD 45 million (approximately KRW 69 billion) from Janssen Biotech following the commercial launch of Lazertinib (brand name Lecraza) in China. The payment was triggered by the achievement of a development milestone related to the combination therapy of Lazertinib and Janssen’s Amivantamab (brand name Rybrevant) for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
In August 2025, the National Medical Products Administration (NMPA) of China approved the combination therapy as a first-line treatment for adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R substitutions.
Lecraza, developed by Yuhan, was approved in January 2021 as Korea’s 31st locally developed new drug, and was out-licensed to Janssen Biotech in November 2018 for global co-development and commercialization. The Lazertinib–Amivantamab combination therapy has already been approved by the U.S. FDA (August 2024), European Commission (late 2024), and Japan’s Ministry of Health, Labour and Welfare (March 2025), marking its continued global expansion into key oncology markets.
To learn more, please click here: https://www.dailypharm.com/Users/News/NewsView.html?ID=328272
#Yuhan, #YuhanUSA, #Lazertinib-Amivantamab combination, #NMPA, #NSCLC